Since 2017, the national healthcare security administration (NHSA) has adjusted the national reimbursement drug list (NRDL) for five times. Normalized adjustment mechanism has been gradually established, and the negotiation mechanism has been increasingly improved. Especially in 2021, the NHSA, upholding integrity and innovation, made an all-round optimization of NRDL adjustment mechanism based on the full summary of the first four rounds of adjustment experience. This paper analyzed the policy optimization of NHSA in the fifth round of NRDL adjustment based on the practice of 2021 NRDL adjustment work, focusing on three aspects: access process, measurement mechanism, and adjustment principles. Furthermore, this paper summarized the experience and put forward development ideas to promote the further improvement of Chinese medical insurance system.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |